Literature DB >> 14667101

The heterogeneity of neuropsychiatric systemic lupus erythematosus is reflected in lack of association with cerebrospinal fluid cytokine profiles.

A Jönsen1, A A Bengtsson, O Nived, B Ryberg, L Truedsson, L Rönnblom, G V Alm, G Sturfelt.   

Abstract

The objective was to study the occurrence of autoantibodies and cytokines in serum and cerebrospinal fluid (CSF) in neuropsychiatric systemic lupus erythematosus (NPSLE). In total, 28 consecutive patients with NPSLE and 16 systemic lupus erythematosus (SLE) patients without neuropsychiatric involvement (non-NPSLE) were studied. IFN-alpha, IL-6, IL-10, soluble terminal complement complex (TCC), anti-ribosomal P protein antibodies (anti-P) and anti-cardiolipin antibodies (aCL) were measured in serum and CSF by immunoassays. Analyses of white blood cell differential count, CSF-albumin/serum-albumin ratio, IgG-index in CSF and isoelectric focusing in serum and CSF were also performed. CSF specimens from 23 healthy individuals were used as controls. IFN-alpha was elevated in the CSF of 5 of 28 NPSLE patients compared to three of 14 among the non-NPSLE patients. IL-6 was elevated in CSF in three of 26 NPSLE patients. Normal concentration of IL-10 was found in CSF in all 27 NPSLE-patients analysed. IFN-alpha in serum was elevated in 18 of 28 NPSLE patients. No distinct clinical phenotype was related to elevated cytokine concentration in serum or CSF. One patient with cerebral involvement complicated by progressive multifocal leukoencephalopathy displayed a very high IFN-alpha concentration in serum. High concentration of TCC was present in CSF from only one patient with systemic vasculitis and focal cerebral symptoms. In conclusion, the results of this study suggest that the diagnostic value of serum and CSF concentrations of IFN-alpha, IL-10, IL-6 and TCC is limited in unselected neuropsychiatric SLE, probably due to the heterogeneity of NPSLE pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14667101     DOI: 10.1191/0961203303lu472sr

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  11 in total

1.  Activation of central nervous system inflammatory pathways by interferon-alpha: relationship to monoamines and depression.

Authors:  Charles L Raison; Andrey S Borisov; Matthias Majer; Daniel F Drake; Giuseppe Pagnoni; Bobbi J Woolwine; Gerald J Vogt; Breanne Massung; Andrew H Miller
Journal:  Biol Psychiatry       Date:  2008-09-18       Impact factor: 13.382

Review 2.  Immunoinflammatory diseases of the central nervous system - the tale of two cytokines.

Authors:  M J Hofer; I L Campbell
Journal:  Br J Pharmacol       Date:  2015-06-12       Impact factor: 8.739

3.  Proliferating brain cells are a target of neurotoxic CSF in systemic autoimmune disease.

Authors:  Boris Sakic; David L Kirkham; David A Ballok; James Mwanjewe; Ian M Fearon; Joseph Macri; Guanhua Yu; Michelle M Sidor; Judah A Denburg; Henry Szechtman; Jonathan Lau; Alexander K Ball; Laurie C Doering
Journal:  J Neuroimmunol       Date:  2005-09-29       Impact factor: 3.478

Review 4.  Neuropsychiatric manifestations in systemic lupus erythematosus: epidemiology, pathophysiology and management.

Authors:  Mariana Postal; Lilian T L Costallat; Simone Appenzeller
Journal:  CNS Drugs       Date:  2011-09-01       Impact factor: 5.749

Review 5.  The Neuro-Immune Pathophysiology of Central and Peripheral Fatigue in Systemic Immune-Inflammatory and Neuro-Immune Diseases.

Authors:  Gerwyn Morris; Michael Berk; Piotr Galecki; Ken Walder; Michael Maes
Journal:  Mol Neurobiol       Date:  2015-01-20       Impact factor: 5.590

6.  Endogenous type-I interferon activity is not associated with depression or fatigue in systemic lupus erythematosus.

Authors:  Erinn S Kellner; Pui Y Lee; Yi Li; Juliana Switanek; Haoyang Zhuang; Mark S Segal; Eric S Sobel; Minoru Satoh; Westley H Reeves
Journal:  J Neuroimmunol       Date:  2010-04-22       Impact factor: 3.478

Review 7.  Cytokines and chemokines in neuropsychiatric syndromes of systemic lupus erythematosus.

Authors:  Hiroshi Okamoto; Akiko Kobayashi; Hisashi Yamanaka
Journal:  J Biomed Biotechnol       Date:  2010-06-29

8.  Potent induction of IFN-alpha and chemokines by autoantibodies in the cerebrospinal fluid of patients with neuropsychiatric lupus.

Authors:  Deanna M Santer; Taku Yoshio; Seiji Minota; Thomas Möller; Keith B Elkon
Journal:  J Immunol       Date:  2009-01-15       Impact factor: 5.422

9.  Autoantibodies as biomarkers for the prediction of neuropsychiatric events in systemic lupus erythematosus.

Authors:  J G Hanly; M B Urowitz; L Su; S-C Bae; C Gordon; A Clarke; S Bernatsky; A Vasudevan; D Isenberg; A Rahman; D J Wallace; P R Fortin; D Gladman; J Romero-Diaz; J Romero-Dirz; J Sanchez-Guerrero; M A Dooley; I Bruce; K Steinsson; M Khamashta; S Manzi; R Ramsey-Goldman; G Sturfelt; O Nived; R van Vollenhoven; M Ramos-Casals; C Aranow; M Mackay; K Kalunian; G S Alarcón; B J Fessler; G Ruiz-Irastorza; M Petri; S Lim; D Kamen; C Peschken; V Farewell; K Thompson; C Theriault; J T Merrill
Journal:  Ann Rheum Dis       Date:  2011-10       Impact factor: 19.103

Review 10.  Activation of type I interferon pathway in systemic lupus erythematosus: association with distinct clinical phenotypes.

Authors:  Theophanis P Karageorgas; Dimitrios D Tseronis; Clio P Mavragani
Journal:  J Biomed Biotechnol       Date:  2011-11-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.